Compare AHMA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | CNTB |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 128.6M |
| IPO Year | 2025 | 2021 |
| Metric | AHMA | CNTB |
|---|---|---|
| Price | $7.04 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 554.7K | 90.3K |
| Earning Date | 12-08-2025 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $19,771,050.00 | $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | $170.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $0.51 |
| 52 Week High | $39.50 | $3.28 |
| Indicator | AHMA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 57.09 |
| Support Level | $6.48 | $2.23 |
| Resistance Level | $32.09 | $2.78 |
| Average True Range (ATR) | 4.72 | 0.28 |
| MACD | -3.17 | 0.02 |
| Stochastic Oscillator | 4.17 | 82.46 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.